| NCT01617655 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolaemia | 2012-06 | PHASE3 |
| NCT03718286 | Population Health Research Institute | ST Elevation Myocardial Infarction|Acute Coronary Syndrome|Hypercholesterolemia|Hyperlipidemias|Dyslipidemias|Physiological Effects of Drugs | 2019-03-11 | PHASE2 |
| NCT03533959 | Kobe University | Coronary Artery Disease Progression | 2017-12-18 | |
| NCT04790513 | LIB Therapeutics LLC | Hypercholesterolemia|Cardiovascular Diseases | 2021-04-22 | PHASE3 |
| NCT01288469 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2011-01 | PHASE2 |
| NCT03207945 | University of California, San Francisco|Massachusetts General Hospital | Dyslipidemias|Cardiovascular Diseases|HIV Infections | 2018-04-30 | PHASE3 |
| NCT01576484 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia|Heterozygous Familial Hypercholesterolemia | 2012-02-28 | PHASE2 |
| NCT06858332 | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 2025-04-15 | |
| NCT02023879 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2013-12-16 | PHASE3 |
| NCT02585778 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolaemia | 2015-10-23 | PHASE3 |
| NCT01644474 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-07 | PHASE3 |
| NCT02957682 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2016-11-02 | PHASE4 |
| NCT02642159 | Sanofi|Regeneron Pharmaceuticals | Dyslipidemia | 2016-03-15 | PHASE4 |
| NCT01288443 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2011-01 | PHASE2 |
| NCT05553834 | Duke University|Regeneron Pharmaceuticals | Non-small Cell Lung Cancer (NSCLC) | 2023-05-16 | PHASE2 |
| NCT01730053 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2012-11-30 | PHASE3 |
| NCT03379558 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2017-12-19 | |
| NCT01812707 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2013-03 | PHASE2 |
| NCT02941016 | Rigshospitalet, Denmark | Lipid Lowering, Vascular Inflammation | 2016-10 | PHASE4 |
| NCT01623115 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-07 | PHASE3 |
| NCT05430828 | Federico II University | Hypercholesterolemia | 2020-03-07 | |
| NCT02107898 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2014-03 | PHASE3 |
| NCT02584504 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2015-11-30 | PHASE3 |
| NCT02326220 | Regeneron Pharmaceuticals|Sanofi | Heterozygous Familial Hypercholesterolemia | 2015-03-31 | PHASE3 |
| NCT03480568 | Baylor Research Institute|Regeneron Pharmaceuticals | Hemodialysis|Peritoneal Dialysis|Hypercholesterolemia|Atherosclerotic Disease | 2018-05-01 | PHASE3 |
| NCT02715726 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2016-07-27 | PHASE3 |
| NCT01507831 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-01 | PHASE3 |
| NCT07477704 | Regeneron Pharmaceuticals | Hypercholesterolemia | 2026-04-14 | PHASE2 |
| NCT02476006 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2015-06-23 | PHASE3 |
| NCT02959047 | University of Virginia|Northwestern University | Peripheral Arterial Disease | 2017-07-17 | PHASE4 |
| NCT01709513 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2012-09-30 | PHASE3 |
| NCT03634293 | Wolfson Medical Center|Assaf-Harofeh Medical Center|Sanofi | Sepsis|Septic Shock | 2019-01 | PHASE2|PHASE3 |
| NCT04613167 | University Medical Centre Ljubljana | Acute Coronary Syndrome|Premature Coronary Heart Disease|Lipoproteinemia|Inflammation|Genetic Polymorphisms | 2020-11-10 | NA |
| NCT03014830 | Washington University School of Medicine | Atherosclerosis|Coronary Heart Disease | 2017-06-01 | PHASE1 |
| NCT04781322 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Associated Liver Disease|Heavy Drinking Behavior | 2021-10-19 | PHASE1 |
| NCT06567418 | Yun Dai Chen|Sanofi | Acute Coronary Syndrome | 2024-08-01 | |
| NCT06052020 | The First Affiliated Hospital with Nanjing Medical University | Stroke|Intracranial Atherosclerotic Stenosis | 2023-09-15 | |
| NCT04189484 | Food and Drug Administration (FDA)|Spaulding Clinical Research LLC | Healthy Subjects|Pharmacokinetics|Pharmacodynamics | 2020-01-07 | PHASE1 |
| NCT03542110 | Minneapolis Heart Institute Foundation|Regeneron Pharmaceuticals | Saphenous Vein Graft Atherosclerosis | 2018-08-04 | PHASE4 |
| NCT03537742 | Stanford University|National Heart, Lung, and Blood Institute (NHLBI) | Vasculopathy | 2019-05-13 | PHASE2 |
| NCT04193306 | Institute for Clinical and Experimental Medicine | Cardiac Allograft Vasculopathy | 2019-11-18 | PHASE4 |
| NCT06385262 | Duke University|Regeneron Pharmaceuticals | Non Small Cell Lung Cancer | 2025-03-17 | PHASE2 |
| NCT03507374 | University of Utah|Regeneron Pharmaceuticals | Stroke|Intracranial Atherosclerosis|Intraplaque Hemorrhage | 2018-10-30 | EARLY_PHASE1 |
| NCT01448304 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2011-06 | PHASE1 |
| NCT05469347 | Jonathan Sevransky|Regeneron Pharmaceuticals | Sepsis | 2023-01-04 | PHASE1 |
| NCT01709500 | Regeneron Pharmaceuticals|Sanofi | Heterozygous Familial Hypercholesterolemia | 2012-12 | PHASE3 |
| NCT01959971 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2013-12 | PHASE1 |
| NCT01663402 | Sanofi|Regeneron Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 2012-10 | PHASE3 |
| NCT01644188 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-08 | PHASE3 |
| NCT03510884 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolaemia | 2018-05-31 | PHASE3 |
| NCT02289963 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2015-01 | PHASE3 |
| NCT03529253 | Kobe University | Coronary Artery Disease|Angina Pectoris | 2018-04-01 | PHASE4 |
| NCT01644175 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-07 | PHASE3 |
| NCT05587621 | Jena University Hospital | ST Elevation Myocardial Infarction|Non-ST Elevation Myocardial Infarction|LDL-cholesterol | 2024-04-01 | NA |
| NCT02984982 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia|Acute Coronary Syndrome | 2016-11-15 | PHASE4 |
| NCT01954394 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2013-12-17 | PHASE3 |
| NCT01723735 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-11 | PHASE1 |
| NCT01266876 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2011-01 | PHASE2 |
| NCT01604824 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2012-02-22 | PHASE2 |
| NCT02890992 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolaemia | 2016-09-15 | PHASE2 |
| NCT03004001 | Gloria Vega|Regeneron Pharmaceuticals|Aventis Pharmaceuticals | Nephrotic Syndrome | 2017-01 | PHASE2 |
| NCT05292404 | Shanghai Tong Ren Hospital|China Cardiovascular Association | Acute Myocardial Infarction | 2022-10-01 | PHASE4 |
| NCT01443650 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2011-07 | PHASE1 |
| NCT02979015 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2016-11-29 | PHASE1 |
| NCT03750760 | Imperial College London|Regeneron Pharmaceuticals|Baim Institute for Clinical Research | Myocardial Infarction|Dyslipidemias | 2020-01 | PHASE4 |
| NCT01926782 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2013-09 | PHASE3 |
| NCT01448317 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2011-05 | PHASE1 |
| NCT05465278 | Fundación Hipercolesterolemia Familiar | Familial Hypercholesterolemia | 2018-05-01 | PHASE4 |
| NCT02938949 | Virginia Commonwealth University|Regeneron Pharmaceuticals|Sanofi | Myocardial Infarction|Hypercholesterolemia | 2017-01 | PHASE4 |
| NCT03355027 | Cambridge University Hospitals NHS Foundation Trust|University of Cambridge | Atherosclerosis|Cardiovascular Diseases | 2017-11-30 | NA |
| NCT01670734 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2012-09 | PHASE1 |
| NCT03415178 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolaemia | 2018-03-29 | PHASE3 |
| NCT06083961 | Sun U. Kwon | Stroke, Acute Ischemic|PCSK9 Inhibitor | 2023-10-15 | PHASE4 |
| NCT01785329 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2013-02 | PHASE1 |
| NCT06080256 | The First Affiliated Hospital with Nanjing Medical University | Intracranial Atherosclerosis|Atherosclerotic Plaque|Stenosis | 2023-12-30 | PHASE3 |
| NCT01448239 | Sanofi|Regeneron Pharmaceuticals | Hypercholesterolemia | 2011-02 | PHASE1 |
| NCT03067844 | Insel Gruppe AG, University Hospital Bern|Regeneron Pharmaceuticals | Coronary Vessel|Coronary Circulation|Atheroma; Myocardial | 2017-04-25 | PHASE3 |
| NCT02992301 | Westside Medical Associates of Los Angeles|University of Washington|Regeneron Pharmaceuticals | Atherosclerosis|Hyperlipidemia | 2016-11 | PHASE4 |
| NCT03156621 | Regeneron Pharmaceuticals|Sanofi | Homozygous Familial Hypercholesterolemia | 2017-10-03 | PHASE3 |
| NCT05001984 | Chang Gung Memorial Hospital|Chang Gung University | Intracranial Atherosclerosis|Acute Ischemic Stroke|ICAS - Intracranial Atherosclerosis | 2021-08-01 | PHASE2 |
| NCT01730040 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2012-10 | PHASE3 |
| NCT03552432 | Kobe University | Coronary Artery Disease|Thin-cap fIbroatheroma | 2017-08-23 | PHASE4 |
| NCT01026597 | Regeneron Pharmaceuticals|Sanofi | Healthy | 2009-11 | PHASE1 |
| NCT01074372 | Regeneron Pharmaceuticals|Sanofi | Healthy Volunteers | 2010-03 | PHASE1 |
| NCT01161082 | Regeneron Pharmaceuticals|Sanofi | Hypercholesterolemia | 2010-06 | PHASE1 |